The growth in this sector has also
been driven largely by blockbuster
IPOs, mergers and multibillion-dollar market valuations for
biotech companies that don’t yet
have a single product for sale.
Investors are divided on what
might happen next.
Bloomberg Business says
“There are reasons to believe
in the boom. Biotech’s current
stock rise has been matched by
Like the whole healthcare industry, the biotech sector is undergoing enormous
change, much of it for the good. On the Nasdaq, biotech has recently had the
biggest weight of any industry, ahead of Internet and computer hardware
companies. The 269 listed biotech companies have shown a more than 500%
return over the past four years. But can that trend continue?
an impressive pace of scientific
achievements. New treatments
in cancer, hepatitis C and genetic
disorders are advancing in the
pipeline or are approved and on
the way to commercial success.” It
points to startups getting moving
with lower investment, greater
access to leading-edge equipment,
and an increasing list of FDA
Here’s a snapshot of where we the
Top 50 (based on revenue) are
today. Companies are ranked by
their 2014 revenue as furnished by
their annual reports and publicly
available sources Edgar and
Morningstar stock information
websites (figures of non-U.S.
companies were converted to U.S.
dollars from various currencies).
Whether you’re a bear or bull on
biotech, it’s an exciting sector of